Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing FcRn-targeting monoclonal antibodies for IgG-mediated autoimmune diseases. The news flow around IMVT reflects its focus on advancing its lead asset IMVT-1402 and its first-generation antibody batoclimab through multiple clinical programs and financing events.
On this page, readers can follow company-issued updates such as quarterly and annual financial results, where Immunovant reports research and development spending, general and administrative expenses, net loss and cash position. These releases often include details on the status of potentially registrational trials of IMVT-1402 in Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis and Sjögren’s disease, as well as a proof-of-concept trial in cutaneous lupus erythematosus.
News items also cover clinical data readouts. Immunovant has announced topline results from a Phase 3 study of batoclimab in myasthenia gravis and initial results from a Phase 2b study in CIDP, highlighting correlations between deeper IgG reductions and improved clinical outcomes. Additional communications describe six‑month off‑treatment remission data from a batoclimab proof‑of‑concept study in uncontrolled Graves’ disease and the design of IMVT‑1402 trials informed by these findings.
Investors can also see coverage of corporate developments, including leadership transitions, changes in board composition and strategic alignment with controlling stockholder Roivant Sciences Ltd. Capital markets updates, such as the pricing of a common stock financing with anticipated gross proceeds of approximately $550 million, are reported through news releases as well.
For anyone tracking IMVT, this news feed provides company-sourced information on clinical milestones, financial reporting, governance changes and equity offerings related to Immunovant’s autoimmune disease pipeline.
Immunovant (Nasdaq: IMVT) reported clinical and corporate updates and Q3 fiscal results for the period ended December 31, 2025. Key points: IMVT-1402 D2T RA trial is fully enrolled with topline data expected in H2 2026, and CLE topline data also expected in H2 2026.
The company completed an underwritten financing that raised approximately $550 million, and held $994.5 million in cash and equivalents as of December 31, 2025, supporting runway toward a potential GD launch. Multiple IMVT-1402 registrational programs remain on track.
Immunovant (Nasdaq: IMVT) will report financial results for the third quarter ended December 31, 2025 and provide a business update on Friday, February 6, 2026 at 8:00 a.m. ET. Investors can access a conference call (phone registration required) hosted with Roivant (Nasdaq: ROIV) and a live webcast. Presentation materials and a webcast archive will be available in the Investors "News & Events" section of Immunovant's website after the call.
Immunovant (Nasdaq: IMVT) priced an underwritten common stock offering to raise approximately $550 million of gross proceeds by selling 26.2 million shares at $21.00 per share. The company said existing cash plus proceeds are expected to fund operating expenses and capital expenditures through a potential commercial launch of IMVT-1402 for Graves’ disease.
Roivant Sciences, the controlling stockholder, agreed to purchase shares. The offering is expected to close on or about December 12, 2025, subject to customary closing conditions, with Leerink Partners as sole underwriter.
Immunovant (Nasdaq: IMVT) reported Q2 results for the period ended September 30, 2025, and provided clinical program updates.
Key points: cash and cash equivalents $521.9 million (runway through the Graves’ disease readout expected in 2027); an uncontrolled Graves’ disease study of IMVT-1402 showed a potentially disease-modifying six‑month off‑treatment outcome; IMVT-1402 development continues across GD, MG, CIDP, D2T RA and Sjögren’s with multiple readouts in 2026–2027. Financials: Q2 R&D $114.2M, Q2 net loss $126.5M ($0.73/sh), six‑month net loss $247.1M ($1.43/sh).
Immunovant (Nasdaq: IMVT) will report financial results for the second quarter ended September 30, 2025 and provide a business update on Monday, November 10, 2025 at 8:00 a.m. ET.
The company said investors can access the Roivant (Nasdaq: ROIV) conference call by phone after registering online and can view the presentation and live webcast via the Investors > News & Events section at https://www.immunovant.com/investors/news-events/ir-calendar. An archived webcast will be available on Immunovant’s website after the call.
Immunovant (NASDAQ: IMVT) has announced groundbreaking six-month remission data for its Graves' disease treatment. In a proof-of-concept study, ~80% (17/21) of patients maintained normal thyroid function six months after stopping batoclimab treatment. Notably, ~50% (8/17) of responders achieved anti-thyroid drug (ATD) free remission.
The study evaluated batoclimab with a 24-week treatment period using a dose step-down protocol (680mg weekly for weeks 0-12, followed by 340mg weekly for weeks 12-24). The company is now advancing with two potentially registrational trials for its lead compound IMVT-1402, testing a 600mg dose for 52 weeks without step-down, with topline results expected in 2027.
Immunovant (Nasdaq: IMVT) announced significant progress in its clinical development programs and financial results for Q2 2025. The company initiated two potentially registrational studies in June 2025: one for IMVT-1402 in Graves' disease (GD) and another for Sjögren's disease (SjD).
The company maintains a strong financial position with $598.9 million in cash, providing runway through GD readout expected in 2027. R&D expenses increased to $101.2 million, up from $75.5 million year-over-year, while net loss widened to $120.6 million ($0.71 per share).
Key upcoming milestones include batoclimab GD remission data in September 2025, and multiple trial results expected in 2026-2027 across various indications including D2T RA, CLE, GD, and MG.
Immunovant (NASDAQ: IMVT) announced significant leadership changes and expansion of its IMVT-1402 development program. Eric Venker, M.D., currently President and COO of Roivant, has been appointed as Immunovant's CEO, replacing Pete Salzmann, M.D. who retired from his role as CEO and Director. Additionally, Tiago Girao has been appointed as CFO, succeeding Renee Barnett.
The company received IND clearance for a potentially registrational program for IMVT-1402 in Sjögren's Disease (SjD), marking its fifth indication, with studies expected to begin in summer 2025. A proof-of-concept study has also been initiated in Cutaneous Lupus Erythematosus (CLE), representing the sixth indication for IMVT-1402. The company confirms its current cash balance provides runway through the expected Graves' Disease readout in 2027.
Immunovant (IMVT) has announced positive results from its clinical trials for batoclimab in two autoimmune conditions. The Phase 3 study in Myasthenia Gravis (MG) achieved its primary endpoint, demonstrating significant improvements in MG-ADL scores: a 5.6-point improvement in the higher dose arm (74% IgG reduction) and a 4.7-point improvement in the lower dose arm (64% IgG reduction).
In the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2b study's Period 1, patients showed a mean improvement of 1.8 in adjusted INCAT disability scores. Notably, an 84% responder rate was observed in patients achieving over 70% IgG reduction. Both studies confirmed that deeper IgG reductions correlated with better clinical outcomes.
The company has active INDs for both conditions and plans to initiate pivotal studies for their lead asset IMVT-1402 in these indications.